Seminar “Role Of Biomarkers In The Diagnosis And Monitoring Of Cardiovascular Diseases”

Tam Anh Research Institute recently organized a seminar titled “Role of Biomarkers In The Diagnosing And Monitoring Cardiovascular Diseases”. The event, held on May 31, generated significant interest among the institute’s healthcare staff.

Seminar Role of biomarkers in the diagnosis and monitoring of cardiovascular diseases

In his welcoming remarks, Assoc. Prof. Pham Nguyen Vinh, PhD, MD, Director of the Center for Cardiology at Tam Anh General Hospital in HCMC, conveyed his deepest gratitude to all those present at the event, as well as to Roche for their support. He also provided valuable insights into the history of biomarker diagnostics in heart failure and stressed the importance of this seminar as a platform for exchanging knowledge and practical experiences in patient diagnosis and treatment.

Assoc. Prof Pham Nguyen Vinh, PhD, MD delivers opening remarks

The seminar covered a variety of important subjects, including:

• Cardiovascular risk and heart failure in diabetic patients.
• The role of Lp(a) in early screening and assessment of atherosclerotic cardiovascular disease.
• Indications for Elecsys ProBNP testing.

Medical professionals of Tam Anh General Hospitals in HCMC attend the seminar

Lam Van Hoang, MD, PhD, Head of Diabetes and Endocrinology Department at Tam Anh General Hospital in HCMC, noted during his presentation that up to 50% of diabetic patients aged 70 and older suffer from heart failure.

The explanation provided highlighted the various factors that contribute to cardiovascular complications in diabetes, including metabolic disorders, structural changes, fibrosis, and vascular damage. He emphasized the importance of NT-proBNP testing in the diagnosis of heart failure, as well as its ability to predict the risk of diabetic heart failure and categorize patients according to age, gender, and comorbidities. A threshold of 125 pg/mL for NT-proBNP indicates a potential risk of cardiovascular problems among individuals with diabetes.

Lam Van Hoang, MD, PhD delivers his presentation

Huynh Thanh Kieu, MD, MsC, head of the Heart Failure Unit of the Center for Cardiology at Tam Anh General Hospital in HCMC, talked about how aggressive multifactorial risk management can lower long-term cardiovascular risk.

She said that Lp(a) has the same structure as LDL, which makes it an atherogenic, and it also has the same structure as plasminogen, which makes it work with clotting, inflammation, and oxidation. Higher levels of Lp(a) raise the chance of heart problems by encouraging atherosclerosis and thrombosis.

Adults should get a Lp(a) test at least once, especially if they have a lipid problem or a family history of early cardiovascular disease. This test can find people who are at a high risk. Strong evidence from genetic and observational studies shows that high Lp(a) levels are linked to ASCVD, aortic valve stenosis, cardiovascular mortality, and mortality from all causes.

Huynh Thanh Kieu, MD, MsC delivers her presentation

A representative from Roche also presented on the current and newly approved indications for Elecsys ProBNP testing. The primary purpose is to assess cardiovascular risk in type 2 diabetic patients and help identify risks in those without a history of cardiovascular disease, aiming to optimize cardiac protective treatment.

A representative from Roche delivers his presentation